Solid Q4 and FY25 Organic Revenue Growth
Q4 organic constant-currency sales grew 5.4% (consolidated); U.S. organic growth 5.7% and International organic growth 5.0%. Full-year 2025 organic constant-currency sales grew 3.9%.
Strong Product Adoption in Joints
U.S. knee revenue +6% in Q4 with Persona OsteoTide ~35% penetration and high adoption of Oxford partial cementless knee; U.S. hip revenue nearly +8% in Q4 with implant C1 representing >35% of U.S. hip stems.
Robotics, Technology and Capital Sales Momentum
U.S. technology/data/bone cement/surgical cells increased >10% in Q4, driven by the strongest robotic capital sales quarter in over two years; continued expansion of robotics/navigation offerings including MBOS (Monogram).
Healthy Cash Generation and Free Cash Flow
Q4 operating cash flow $517M and Q4 free cash flow $368M; full-year 2025 free cash flow $1.172B, up >11% year-over-year; company expects free cash flow growth of 8%–10% in 2026 and ~80% FCF conversion.
Adjusted EPS Growth and Share Count Reduction
Q4 adjusted diluted EPS $2.42, up 4.8% year-over-year; full-year adjusted EPS $8.20. Fully diluted shares were 198.1M (down YoY), aided by share repurchases of $250M in Q4.
Capital Return and Balance Sheet Actions
Board approved buyback authority and activity: $250M repurchased in Q4 2025, board authorization up to $1.5B, and management disclosed share buybacks in 2026 of up to $750M; cash & cash equivalents ~ $592M at year-end.
Robust Innovation and Portfolio Progress
Management highlighted closed core portfolio gaps, the 'magnificent seven' platform, iodine-coated devices (Japan launch), Oxford partial cementless knee, and Monogram/MBOS—pipeline ~3x what it was a few years ago with multiple launches planned in 2026.
Progress on U.S. Go-to-Market Changes
Company has completed ~one-third of the transition to a dedicated/specialized U.S. sales channel; plans to complete majority conversion by end of 2027 and to add specialized reps (e.g., 200+ robotics reps) to target higher growth areas like SCT and ASCs.